3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Preleukemia
1
Myelodysplastic Syndromes
1
Leukemia
1
Hematologic Diseases
1
Cytopenia
1
Bone Marrow Diseases
1
Anemia
1
Interventions
luspatercept
4
Biopsy
4
Lenalidomide
3
Epoetin Alfa
3
Cyclophosphamide
3
Busulfan
3
ruxolitinib
2
fludarabine
2
Filgrastim
2
Cyclosporine
2
Antilymphocyte Serum
2
AP 1903 reagent
2
ACE-011
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
vactosertib
1
trametinib
1
thymoglobulin
1
siltuximab
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
olaparib
1
neratinib
1
lorlatinib
1
lenvatinib
1
idelalisib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anemia
×
Sertraline
×
Myeloid
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled